Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October

GlobeNewswire September 19, 2018

Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference

GlobeNewswire August 28, 2018

Analysis: Positioning to Benefit within Noble, Spero Therapeutics, AK Steel Holding, Matrix Service, First Internet, and Cray — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire August 22, 2018

Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors

GlobeNewswire August 14, 2018

Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview

GlobeNewswire August 9, 2018

Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development

GlobeNewswire July 16, 2018

Spero Therapeutics Announces Pricing of Securities Offering

GlobeNewswire July 12, 2018

Spero Therapeutics Announces Proposed Offering of Common Stock

GlobeNewswire July 9, 2018

Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

GlobeNewswire July 9, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Jabil, Gladstone Investment, Spero Therapeutics, Jagged Peak Energy, Sabre, and Zions — New Research Emphasizes Economic Growth

GlobeNewswire June 11, 2018

Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

PR Newswire June 6, 2018

Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018

GlobeNewswire June 5, 2018

Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June

GlobeNewswire June 1, 2018

Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform

GlobeNewswire May 23, 2018

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Benzinga.com  May 19, 2018

Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update

GlobeNewswire May 10, 2018

Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May

GlobeNewswire May 1, 2018

Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

PR Newswire April 20, 2018

Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases

GlobeNewswire April 16, 2018

Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology

GlobeNewswire April 12, 2018